Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma.

Trial Profile

Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top